Vasculitis syndromes: Which maintenance therapy for ANCA vasculitis?

Nature Reviews Nephrology

Volumn 5, Issue 5, 2009, Pages 254-256

  Nachman, Patrick H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RISK FACTOR; SHORT SURVEY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS; IMMUNOLOGY; NOTE; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; VASCULITIS;

EID: 67650354217     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.52     Document Type: Short Survey

References (12)

1. Pagnoux, C. et al. Azathioprine or methotrexate maintenance for AnCAassociated vasculitis. N. Engl. J. Med. 359, 2790-2803 (2008).
2. Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621-631 (2005).
3. Pagnoux, C. et al. Predictors of treatment resistance and relapse in AnCA small vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908-2918 (2008).
4. Salama, A. D., Ryba, M., Levy, J., Pusey, C. D. & Gaskin, G. 30 year follow up of 400 patients with AnCA associated vasculitis: predictors of relapse and survival. J. Am. Soc. Nephrol. 17, 732A (2006).
5. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003). (Pubitemid 36765101)
6. De Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461-2469 (2005).
7. Metzler, C. et al. elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in wegener's granulomatosis. Rheumatology (Oxford) 46, 1087-1091 (2007).
8. Stegeman, C. A., Tervaert, J. W., Dde Jong, P. E. & Kallenberg, C. G. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of wegener's granulomatosis. Dutch Co-Trimoxazole wegener study Group. N. Engl. J. Med. 335, 16-20 (1996).
9. Wegener's Granulomatosis etanercept Trial (wGeT) Research Group. etanercept plus standard therapy for wegener's granulomatosis. N. Engl. J. Med. 352, 351-361 (2005).
10. Koukoulaki, M. & Jayne, D. R. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodiesassociated systemic vasculitis. Nephron Clin. Pract. 102, c100-c107 (2006).
11. Jones, R., Walsh, M. & Jayne, D. for the european vasculitis study Group. Randomised Trial of Rituximab versus Cyclophosphamide for AnCA Associated Renal vasculitis: RiTUXvAs. J. Am. Soc. Nephrol. 19, 61A (2008).
12. Rituximab for the treatment of wegener's Granulomatosis and Microscopic Polyangiitis (RAve) http://clinicaltrials.gov/ct2/show/ nCT00104299.